Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2994.14% is 268% below its 5-year average of -812.97%, near the high end of its 5-year range (-33184.62%–3457.84%).
69.43% above its 12-month average of -9793.99%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -33184.62%.
EBITDA MARGIN
-2994.14%
EBITDA MARGIN AVG TTM
-9793.99%
EBITDA MARGIN AVG 3Y
-1522.44%
EBITDA MARGIN AVG 5Y
-812.97%
EBITDA MARGIN AVG 10Y
-1133.07%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+69.43%
CURRENT VS 3Y AVG
-96.67%
CURRENT VS 5Y AVG
-268.29%
CURRENT VS 10Y AVG
-164.25%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cartesian Therapeutics, Inc.
Market Cap
$203.92M
EBITDA Margin
-2994.14%
TTM Avg
-9793.99%
3Y Avg
-1522.44%
5Y Avg
-812.97%
Market Cap
$202.26M
EBITDA Margin
-1195.14%
TTM Avg
-710.65%
3Y Avg
-586.79%
5Y Avg
-586.79%
Market Cap
$206.05M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$208.37M
EBITDA Margin
-611.99%
TTM Avg
-293.95%
3Y Avg
-196.05%
5Y Avg
-196.05%
Market Cap
$211.33M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $203.92M | -2994.14% | -9793.99% | -1522.44% | -812.97% |
| Surrozen, Inc. (SRZN)vs › | $202.26M | -1195.14% | -710.65% | -586.79% | -586.79% |
| Alector, Inc. (ALEC)vs › | $206.05M | -646.93% | -391.16% | -256.59% | -321.84% |
| Sionna Therapeutics, Inc. (SION)vs › | $206.19M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $200.00M | -17.95% | -19.68% | -44.09% | -43.18% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | -611.99% | -293.95% | -196.05% | -196.05% |
| Pro-Dex, Inc. (PDEX)vs › | $208.71M | 18.55% | 18.23% | 16.57% | 15.69% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 43.70% | -4.00% | -127.66% | -437.76% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
Gross Margin
100.0%
EBITDA Margin
-2994.1%
Operating Margin
-3099.9%
Net Margin
-10422.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -33184.62% |
| 2025-12-31 | -2252.48% |
| 2025-09-30 | -4526.55% |
| 2025-06-30 | -7121.48% |
| 2025-03-31 | -1884.82% |
| 2024-12-31 | 3457.84% |
| 2024-09-30 | -4467.44% |
| 2024-06-30 | 41.72% |
| 2024-03-31 | -225.43% |
| 2023-12-31 | -436.24% |
| 2023-09-30 | -196.55% |
| 2023-06-30 | -351.72% |
| 2023-03-31 | -306.08% |
| 2022-12-31 | -46.97% |
| 2022-09-30 | -5.12% |
| 2022-06-30 | 36.56% |
| 2022-03-31 | 33.58% |
| 2021-12-31 | 14.70% |
| 2021-09-30 | -5.51% |
| 2021-06-30 | 5.26% |
| 2021-03-31 | -60.44% |
| 2020-12-31 | -64.04% |
| 2020-09-30 | -292.72% |
| 2019-12-31 | -166.29% |
| 2019-06-30 | -123546.15% |
| 2019-03-31 | -116750.00% |
| 2018-12-31 | -1585.05% |
| 2017-12-31 | -112317.65% |
| 2017-09-30 | -50640.74% |
| 2017-06-30 | -60230.77% |
| 2017-03-31 | -10662.04% |
| 2016-12-31 | -464.27% |
| 2016-09-30 | -695.32% |
| 2016-06-30 | -308.13% |
| 2016-03-31 | -323.90% |
| 2015-12-31 | -324.70% |
| 2015-09-30 | -364.03% |
| 2015-06-30 | -474.43% |
| 2015-03-31 | -543.23% |
